Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

More... (http://www.news-medical.net/news/20120509/Provectus-announces-final-data-from-PV-10-Phase-2-trial-on-metastatic-melanoma.aspx)